COMPARATIVE STUDY
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Outcomes of NIDEK optical path difference custom ablation treatments (OPDCAT) for myopia with or without astigmatism.

PURPOSE: To report refractive and visual acuity outcomes using wavefront-guided optical path difference custom ablation treatments (OPDCAT; NIDEK Co Ltd) for myopia and myopic astigmatism.

METHODS: One hundred eyes of 50 patients with preoperative manifest refraction spherical equivalent (MRSE) of 4.62+/-1.30 diopters (D) (range: -1.38 to -7.25 D) with mean astigmatism of -0.57+/-0.37 D (range: 0 to -1.75 D) underwent LASIK with OPDCAT. Eyes that had > or =5 microm of irregularity preoperatively underwent additional irregularity treatment (irregularity group) and were compared with eyes that did not undergo irregularity ablation (aspheric group). An independent-samples t test was used to analyze refractive outcomes at 3 months postoperatively. A P value <.05 was considered statistically significant.

RESULTS: The mean postoperative MRSE was 0.18+/-0.35 D (range: -0.63 to 1.00 D). Ninety-six (96%) eyes had uncorrected visual acuity of 20/20 or better and 87 (87%) eyes were within +/-0.50 D of the intended correction. No eyes lost two or more lines of best spectacle-corrected visual acuity (BSCVA), 1 (1%) eye lost one line of BSCVA, and 99 (99%) eyes maintained gained lines of BSCVA. The MRSE changed 0.02 D between 1 and 3 months postoperatively. A statistically significant increase was noted in higher order aberrations in the entire cohort (P<.05) with lower induced higher order aberration and coma aberrations in the irregularity group (P<.05).

CONCLUSIONS: LASIK using wavefront-guided OPDCAT ablation with or without irregularity is safe and efficacious for the treatment of myopia with astigmatism. The irregularity treatment induces fewer higher order aberrations than aspheric ablation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app